Revenue of KRW 442.2 billion; operating profit of KRW 132.6 billion
Operating profit excluding milestones up 21.3%
Year-to-date operating profit reached 97% of last year's total

Samsung Bioepis continued to post steady growth in the third quarter, driven mainly by sales of its biosimilar products. Excluding one-time milestone revenue, operating profit rose more than 20% from a year earlier.

Samsung Bioepis headquarters in Songdo, Yeonsu-gu, Incheon. The Asia Business Daily DB.

Samsung Bioepis headquarters in Songdo, Yeonsu-gu, Incheon. The Asia Business Daily DB.

View original image

Samsung Bioepis said on Oct. 28 that it recorded revenue of KRW 442.2 billion and operating profit of KRW 132.6 billion in the third quarter of this year. Revenue increased by KRW 1.2 billion, or 0.3%, and operating profit by KRW 3.6 billion, or 2.8%, from the same period a year earlier. Compared with the previous quarter, revenue rose 12.7% and operating profit increased 53.1%.


Sales of products, excluding milestone revenue received for research and development achievements, improved more significantly. Revenue excluding milestones came to KRW 416.5 billion, up 4.1% from the same period a year earlier, while operating profit reached KRW 106.9 billion, an increase of 21.3%. Growth was driven by higher global sales of SB12, a Soliris biosimilar whose active ingredient is eculizumab, and SB17, a Stelara biosimilar whose active ingredient is ustekinumab.


Samsung Bioepis recorded cumulative revenue of KRW 1.2893 trillion and operating profit of KRW 363.2 billion in the first three quarters of this year. Its operating profit in just the first three quarters amounted to 97% of last year's full-year figure of KRW 375.9 billion.


The company is also accelerating development of its follow-on pipeline. Samsung Bioepis currently sells 11 biosimilars in global markets and is developing nine follow-on biosimilars targeting blockbuster drugs approaching patent expiration. Its Keytruda biosimilar SB27 demonstrated equivalence to the original drug in a global Phase 3 clinical trial in June, then became the first in South Korea to enter the product approval process in August. Earlier this month, the company also signed a partnership agreement with Teva for the U.S. and European commercialization of two biosimilar candidates for Fasenra and Ilaris.


New drug development is also underway. SBE303, the company's first novel drug candidate, is an antibody-drug conjugate (ADC) for solid tumors. It has been in a global Phase 1 clinical trial since March this year and recently received Fast Track designation from the U.S. Food and Drug Administration (FDA). The company is conducting preclinical research on its follow-on ADC candidate SBE313 and its long-acting obesity treatment candidate SBE501.



Samsung Epis Holdings, the holding company, reported third-quarter consolidated revenue of KRW 441.9 billion and operating profit of KRW 105 billion.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing